[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Huazhong University of Science and Technology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":629},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,44,70,100,128,151,185,204,231,256,277,294,310,331,351,376,397,418,446,468,499,533,557,577,604],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100054244","phase-4-the-ed95-of-ciprofol-for-laryngeal-mask-airway-insertion-with-fentanyl-in-children-a-biased-coin-dose-finding-trial-100054244",false,"NCT07697404","The ED95 of Ciprofol for Laryngeal Mask Airway Insertion With Fentanyl in Children: A Biased-Coin Dose-Finding Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status I or II\n* Aged 1 to 12 years\n* Scheduled for elective surgery requiring general anesthesia with laryngeal mask airway (LMA) insertion (e.g., ophthalmic surgery, skin lesion excision, minor abdominal or urological procedures, with expected surgical duration ≤ 2 hours)\n* Written informed consent obtained from parents or legal guardians\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to ciprofol, fentanyl, or any study-related drugs\n* Intellectual disability, cognitive-affective disorders, psychiatric or neurological diseases\n* Inability to cooperate with peripheral intravenous cannulation\n* History of reactive airway disease or suspected difficult airway\n* Body mass index (BMI) ≥ 30 kg\u002Fm² or ≤ 15 kg\u002Fm²\n* History of sedative medication use\n* Inability to understand the study protocol or participation in another clinical trial within the past 30 days","ALL","1 Year","12 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Ciprofol is a novel intravenous anesthetic with a pharmacological profile similar to propofol but with a lower incidence of injection pain, hypotension, and respiratory depression. For pediatric day-case surgeries, laryngeal mask airway (LMA) insertion without neuromuscular blockers is increasingly preferred. While opioids are often combined with hypnotics to optimize insertion conditions, the optimal bolus dose of ciprofol when co-administered with a standard dose of fentanyl for LMA insertion in children remains unknown. This study aims to determine the 95% effective dose (ED95) of a single intravenous bolus of ciprofol, combined with a fixed dose of fentanyl (1 μg\u002Fkg), for successful LMA insertion in children aged 1-12 years during general anesthesia induction.",[27,28,29,30],"Pediatric","Anesthesia Induction","Ciprofol","Laryngeal Mask Airway","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2026-06-15",{"date":39,"type":21},"2028-12-01",{"name":41,"class":42},"Huazhong University of Science and Technology","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100630332","effect-of-acupuncture-on-the-success-rate-in-patients-with-recurrent-implantation-failure-100630332","NCT07486297","Effect of Acupuncture on the Success Rate in Patients With Recurrent Implantation Failure","A Multicenter Randomized Controlled Trial Evaluating the Effect of Acupuncture on the Success Rate in Patients With Recurrent Implantation Failure","Inclusion Criteria:\n\n1. Meets the criteria for RIF diagnosis (≥ 2 instances of unsuccessful transfer of high-quality embryos).\n2. Age: 20 to 40 years old.\n3. Planning for a cycle involving the transfer of frozen-thawed embryos (FET).\n4. Possession of a transplantable D3 frozen embryo (≥6 cells) or a frozen blastocyst (≥3BC).\n5. Estradiol-progesterone replacement therapy: endometrial thickness ≥ 7 mm within the period of endometrial transformation.\n\nExclusion Criteria:\n\n1. Individuals planning to undergo preimplantation genetic diagnosis (PGD).\n2. Recipients of egg donations.\n3. Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms).\n4. Patients with known embryo-related factors leading to implantation failure.\n5. Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on).\n6. Recurrent spontaneous abortions (loss of a fetus before 28 weeks of gestation occurring twice or more).\n7. Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months.\n8. Individuals with untreated hydrosalpinx;\n9. Individuals with a Body Mass Index (BMI) below 18 and above 25 kg\u002Fm2.\n10. Men with severe abnormalities in semen quality. Individuals with a history of needle phobia.","FEMALE","20 Years","40 Years",{"count":55,"type":21},208,[57],"NA","To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of pressing therapy on the success rate in patients with recurrent implantation failure.",[60],"Implantation Failure","NOT_YET_RECRUITING","2026-06-20",{"date":64,"type":35},"2026-06-25",{"date":66,"type":21},"2026-06-30",{"date":68,"type":21},"2028-06-30",{"name":41,"class":42},{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100639156","effects-of-inulin-on-cardiometabolic-risk-factors-in-individuals-using-glucagon-like-peptide-1-receptor-agonists-glp-1-ra--medications-for-weight-loss-100639156","NCT07611552","Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss","The Effect of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Medications for Weight Loss: a Randomized Double-blind Controlled Trial","Inclusion criteria:\n\n* Be overweight or obese (meeting any of the following criteria):\n\n  1. Obesity: BMI \\>=28 kg\u002Fm²;\n  2. Overweight (BMI \\>= 24 kg\u002Fm²) with at least one body weight-related comorbidity: obstructive sleep apnea syndrome, prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia, polycystic ovary syndrome, or non-alcoholic fatty liver disease.\n* Must have received GLP-1 RA drugs (Semaglutide, Liraglutide, Benaglutide, Tirzepatide, or Mazdutide) for weight-loss intervention for at least 3 months, and plan to continue using them for the next six months.\n* Age 18-64 years.\n* Consent to participate and sign the informed consent form.\n\nExclusion criteria:\n\n* Currently using non-GLP-1 RA medications for weight-loss, or have undergone or plan to undergo weight-loss procedures within the next 4 months;\n* Long-term user of prebiotics or probiotics (excluding fermented dairy products such as yogurt);\n* Be allergic or intolerance to inulin-type substances;\n* Have participated in in other clinical trials within the past 3 months or are currently participating in other clinical trials;\n* Plan to be pregnant within the next year, are currently pregnant, or are breastfeeding;\n* Deemed unsuitable for participation by the investigator's judgment.","18 Years","64 Years",{"count":80,"type":21},600,[57],"The goal of this double-blind randomized placebo-controlled supplement study is to investigate if the supplement of inulin (prebiotics, 10 grams per day) has beneficial effects on cardiometabolic risk factors in overweight or obese individuals receiving glucagon-like peptide-1 receptor agonists (GLP-1 RA) medications for weight loss.",[84],"Obesity & Overweight",[86,87,88,89,90],"weight loss","cardiometabolic risk factors","prebiotics","lipids","glucagon-like peptide-1 receptor agonists (GLP-1 RA)","2026-06-01",{"date":93,"type":35},"2026-06-03",{"date":95,"type":21},"2026-06",{"date":97,"type":21},"2026-11",{"name":41,"class":42},5,{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":43},"100516542","phase-2-zanubrutinib-combined-with-r-chop-in-the-treatment-of-newly-diagnosed-dlbcl-with-p53-protein-expression-100516542","NCT06005870","Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression","Zanubrutinib Combined With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in the Treatment of Newly Diagnosed Diffuse Large B-cell Lymphoma With p53 Protein Expression","Inclusion Criteria:\n\n1. Age ≥18 years, ≤ 75 years, both sexes;\n2. Diff use large B-cell lymphoma diagnosed by histopathology without previous systemic DLBCL treatment;\n3. ECOG score: 0-2;\n4. Predicted survival ≥3 months;\n5. Patients with positive p53 expression detected by immunohistochemistry (≥50% );\n6. The patients had certain conditions of organ function reserve, and the laboratory tests within 1 week before enrollment met the following conditions:\n\nBlood routine: neutrophil count (NEUT) ≥1.5×10\\^9\u002FL, platelet count (PLT)\n\n≥75×10\\^9\u002FL, hemoglobin (HGB) ≥80 g\u002FL; G-CSF was not used in the past 7 days (the researchers judged that the lymphoma-induced cytopenia could be included).\n\nLiver function: Total bilirubin (TBIL) ≤1.5× upper limit of the normal range (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; If liver metastases were present, TBIL≤3×ULN, ALT and AST≤5×ULN; Renal function: serum creatinine (Cr) ≤2.0×ULN or creatinine clearance (CCr) ≥60ml\u002Fmin;\n\nCardiac function: LVEF≥50%, ECG did not indicate any acute myocardial infarction, arrhythmia, or atrioventricular conduction block above grade I;\n\nThyroid function: thyroid stimulating hormone (TSH) was within the normal range. If TSH is abnormal, free triiodothyronine (FT3) and free thyroxine (FT4) should be within the normal range or abnormal without clinical significance.\n\n1. According to the Lugano2014 assessment criteria, patients must have measurable lesions, defined as the longest diameter of at least one nodule \\> 1.5cm, or the longest diameter of at least one nodule \\> 1cm, and at least two vertical diameters that can be accurately measured.\n2. Patients volunteered to participate in the trial, understood the study procedure, and were able to sign in-person informed consent.\n\nExclusion Criteria:\n\n1. Patients with definite lymphoma central nervous system (CNS) infiltration, including brain parenchyma, meningeal invasion, or spinal cord compression;\n2. severe or uncontrolled infection;\n3. with active autoimmune disease;\n4. Other serious medical conditions, such as uncontrolled diabetes, gastric ulcers, other serious cardiopulmonary diseases, etc. (the decision was left to the investigator);\n5. patients who received the live attenuated vaccine within 4 weeks before the first dose or planned to receive the live attenuated vaccine during the study;\n6. The subject has previous or co -e xis ting other malignant tumors; Patients with basal cell carcinoma of the skin and uterine and neck carcinoma in situ who had been cured for more than 3 years, and patients with other malignant tumors who had been cured for more than 5 years were considered for inclusion.\n7. HIV-positive patients with active hepatitis B ( HBV-DNA \\> 100 copies\u002Fm L), positive HCV antibody, or abnormal HCV-RNA\n8. Women who were pregnant or lactating, women who planned to become pregnant between the study period and 6 months after the last dose, or men whose partners planned to become pregnant, who were unwilling to use a medically approve defective contraceptive method (e.g., intrauterine device or condom ) during the trial;\n9. were allergic to any of the drugs in the study protocol;\n10. ineligible for inclusion as judged by the investigator ;","75 Years",{"count":109,"type":21},41,[111],"PHASE2","This study aim to evaluate the efficacy and safety of zanubrutinib combined with R-CHOP in the treatment of DLBCL patients with p53 protein expression.",[114],"Diffuse Large B Cell Lymphoma",[116,117,118,119],"DLBCL","Diffuse Large b-cell lymphoma","p53","zanubrutinib","2026-05-14",{"date":122,"type":35},"2026-05-18",{"date":124,"type":35},"2022-11-26",{"date":126,"type":21},"2026-12",{"name":41,"class":42},{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":43},"100635672","phase-4-ai-assisted-multi-domain-lifestyle-versus-tirzepatide-for-weight-loss-maintenance-in-adults-with-type-2-diabetes-aim-maintain-100635672","NCT07555730","AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)","Effect of AI-assisted Multi-domain Lifestyle Intervention Versus Tirzepatide Treatment on Weight Loss Maintenance in Adults With Type 2 Diabetes: a Randomized Clinical Trial.","Inclusion Criteria:\n\n1. Male or female participants aged 18 to 65 years at the time of signing informed consent;\n2. Body Mass Index (BMI) ≥27.0 kg\u002Fm²;\n3. Type 2 diabetes mellitus diagnosed by physicians within the past 5 years prior to screening.\n4. Voluntary participation and provide written informed consent.\n\nExclusion Criteria:\n\n1. History of type 1 diabetes mellitus or other types of diabetes, or treatment with insulin.\n2. History of obesity attributable to endocrine disorders or monogenic mutations.\n3. A self-reported change in body weight ≥5.0% within 3 months prior to the day of screening.\n4. Use of medications or products causing weight changes or affecting weight assessment within 3 months prior to the day of screening;\n5. History of major adverse cardiovascular or cerebrovascular events within 6 months before screening (e.g., angina, myocardial infarction, arrhythmia, stroke, intracranial hemorrhage).\n6. History of acute or chronic pancreatitis, pancreatic injury, or other high-risk factors for pancreatitis.\n7. History of cancers (except for localized basal cell carcinoma, adenocarcinoma in situ of cervix or prostate carcinoma in situ); personal or family history of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia syndrome (MEN2), or history of thyroid nodules (category IV or higher).\n8. History of organ transplantation, congenital or acquired immunodeficiency disorders.\n9. History of schizophrenia or major depressive disorder or other severe psychiatric disorders.\n10. Poorly controlled hypertension at screening (systolic blood pressure (SBP) ≥160 mmHg and\u002For diastolic blood pressure (DBP) ≥100 mmHg despite at least 4 weeks of conventional antihypertensive therapy).\n11. History of clinically significant gastric emptying abnormalities, or history of severe chronic gastrointestinal disease, or history of diabetic gastroparesis, or long-term use of drugs that directly affect gastrointestinal motility, or history of gastrointestinal surgery.\n12. Those who are known to be allergic to any component of GLP-1 receptor agonists drugs, or have more than two allergies, or be allergic to soy, dairy, or similar foods.\n13. Laboratory evaluation at screening meet any of the following criteria:\n\n    * Calcitonin ≥50 pg\u002FmL;\n    * Thyroid stimulating hormone (TSH) \\>6.0 or \\\u003C0.4 mIU\u002FL;\n    * Fasting C-peptide \\\u003C0.81 ng\u002FmL;\n    * Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \\>2.5 × upper limit of normal (ULN) or total bilirubin (TBIL) \\>2.5 × ULN (except Gilbert's syndrome with conjugated bilirubin \\\u003C35%);\n    * Triglycerides ≥5.7 mmol\u002FL;\n    * Serum amylase \\>2.5 × ULN;\n    * eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²\n14. History of uncontrolled and potentially unstable proliferative retinopathy or maculopathy within 1 year prior to screening, or history of diabetic ketoacidosis, diabetic non-ketotic hyperosmolar coma, or severe metabolic disturbances with neurological and psychiatric disorders.\n15. History of clinically significant anemia, or epilepsy, or syncope or cardiac conditions (e.g. cardiac arrest, arrhythmias, atrioventricular block, structural heart disease, torsades de pointes).\n16. Patients with active bacterial, viral, or fungal infections requiring hospitalization or antibiotic treatment.\n17. History of infectious diseases such as human immunodeficiency virus (HIV), syphilis, or active hepatitis.\n18. Female patients who are pregnant, lactating, or planning to become pregnant within the next two years.\n19. Participation in other clinical trial within 3 months before screening or currently enrolled in other clinical trial study.\n20. History of drug abuse or alcohol dependence within 6 months before screening.\n21. Any other reasons that researchers deem to unsuitable for participation in this study.","65 Years",{"count":137,"type":21},400,[24],"This is a randomized controlled trial to compare the effect of AI-assisted multi-domain lifestyle and continued tirzepatide on body weight loss maintenance. The study consists of two phases: a 20-week lead-in phase, during which all participants will receive weekly subcutaneous tirzepatide at the maximum tolerated dose (MTD), followed by a 52-week intervention phase.\n\nParticipants who meet the randomization criteria after the lead-in phase will be randomly assigned to either AI-assisted multi-domain lifestyle intervention or tirzepatide 5 mg",[141,142],"Overweight or Obesity; Type 2 Diabetes","Weight Loss Maintenance","2026-04-21",{"date":145,"type":35},"2026-04-29",{"date":147,"type":21},"2026-04-30",{"date":149,"type":21},"2028-09-30",{"name":41,"class":42},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":168,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":184,"locationsCount":43},"100632144","liposomal-bupivacaine-versus-ropivacaine-with-perineural-dexamethasone-or-dexmedetomidine-as-adjuncts-for-adductor-canal-block-combined-with-ipack-block-in-total-knee-arthroplasty-100632144","NCT07509866","Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal Block Combined With IPACK Block in Total Knee Arthroplasty","A Randomized Trial of Liposomal Bupivacaine, Ropivacaine With Perineural Dexamethasone, and Ropivacaine With Perineural Dexmedetomidine for Adductor Canal Block Combined With IPACK Block in Total Knee Arthroplasty","Inclusion Criteria:\n\n* Patients scheduled for elective primary unilateral total knee arthroplasty\n* Age ≥ 18 years and ≤ 80 years\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Body mass index (BMI) ≥ 18 kg\u002Fm² and ≤ 35 kg\u002Fm²\n* Ability to understand and provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or contraindication to local anesthetics (bupivacaine, ropivacaine), dexamethasone, dexmedetomidine, or opioids\n* Infection at the injection site\n* Coagulopathy or current use of anticoagulants\n* Severe cardiovascular disease (New York Heart Association \\[NYHA\\] functional class III or IV, or recent myocardial infarction within 6 months)\n* Severe hepatic impairment (Child-Pugh class C) or renal impairment (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Uncontrolled hypertension (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg despite medical therapy)\n* Uncontrolled diabetes mellitus (HbA1c \\> 8.5%)\n* Bilateral TKA or revision TKA\n* Chronic opioid use (daily opioid consumption for \\> 3 months prior to surgery)\n* Participation in another interventional clinical trial within 30 days prior to enrollment\n* Inability to communicate with study personnel or complete pain assessments (e.g., language barrier, cognitive impairment)","80 Years",{"count":160,"type":21},90,[57],"Effective postoperative pain management remains a cornerstone of enhanced recovery protocols following total knee arthroplasty (TKA). Inadequate analgesia not only compromises patient satisfaction but also impedes early mobilization and rehabilitation, thereby increasing the risk of perioperative complications. Current multimodal analgesic strategies frequently incorporate regional techniques, with the adductor canal block (ACB) and infiltration between the popliteal artery and capsule of the knee (IPACK) block emerging as established modalities that provide motor-sparing analgesia.\n\nDespite their widespread adoption, the optimal local anesthetic regimen for these blocks remains undefined. While liposomal bupivacaine has garnered interest for its extended duration of action, its clinical efficacy relative to conventional local anesthetics combined with perineural adjuncts remains a subject of ongoing debate. Specifically, perineural dexamethasone and dexmedetomidine have each demonstrated the capacity to prolong the analgesic duration of ropivacaine; however, direct comparative data among these three distinct strategies-liposomal bupivacaine alone versus ropivacaine supplemented with either adjunct-are notably limited.\n\nGiven the absence of head-to-head randomized trials evaluating these three clinically viable techniques, the optimal approach to maximize analgesic duration while minimizing opioid-related adverse effects remains unclear. This study therefore aims to compare the analgesic efficacy and safety profiles of liposomal bupivacaine, ropivacaine with perineural dexamethasone, and ropivacaine with perineural dexmedetomidine when administered via ACB and IPACK blocks in patients undergoing TKA.",[164,165,166,167],"Total Knee Anthroplasty","Nerve Block","Ropivacaine","Liposomal Bupivacaine",[169,170,171,172,173,174,175,176,177],"total knee arthroplasty","adductor canal block","IPACK block","liposomal bupivacaine","ropivacaine","perineural adjuncts","dexamethasone","dexmedetomidine","multimodal analgesia","2026-04-09",{"date":180,"type":35},"2026-04-14",{"date":178,"type":35},{"date":183,"type":21},"2026-12-30",{"name":41,"class":42},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":4},"100633507","study-on-biomarkers-of-immune-related-adverse-events-100633507","NCT07527585","Study on Biomarkers of Immune-Related Adverse Events","Inclusion Criteria:\n\n1. Age \\>18 years;\n2. Karnofsky Performance Status (KPS) \\>60;\n3. Expected to receive at least one cycle of immune checkpoint inhibitor therapy;\n4. Expected survival \\>6 months.\n\nExclusion Criteria:\n\n1. Prior treatment with immune checkpoint inhibitors;\n2. Active autoimmune diseases (including systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, myasthenia gravis, scleroderma, etc.);\n3. Use of systemic immunosuppressive agents within 14 days prior to enrollment (prednisone \\>10 mg\u002Fday or equivalent);\n4. Inability to provide biological samples.",{"count":192,"type":21},440,"OBSERVATIONAL","1. To identify biomarkers of immune-related adverse events;\n2. To develop a predictive model for immune-related adverse events.",[196],"Immune-Related Adverse Events","2026-04-07",{"date":180,"type":35},{"date":200,"type":21},"2026-04",{"date":202,"type":21},"2032-12",{"name":41,"class":42},{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":43},"100618078","minimum-effective-dose-of-ropivacaine-for-ultrasound-guided-interscalene-block-100618078","NCT07326943","Minimum Effective Dose of Ropivacaine for Ultrasound-guided Interscalene Block","Minimum Effective Dose of Ropivacaine 0.5% for Ultrasound-guided Interscalene Block Targeting the C7 Nerve Root in Hand and Forearm Surgery","Inclusion Criteria:\n\n* Age range: 18-60 years old\n* ASAⅠ\\~II\n* BMI between 18 and 30kg\u002Fm2\n* Patients undergoing hand or forearm surgery\n* Sign informed consent form\n\nExclusion Criteria:\n\n* Refusal to participate in the experiment\n* Merge peripheral nerve diseases\n* Lidocaine and ropivacaine allergy\n* Pregnant women\n* Obstructive or restrictive lung disease\n* Coagulation dysfunction\n* Long term use of opioid drugs\n* Infection, tumor or surgical history at the puncture site","60 Years",{"count":213,"type":21},56,[57],"Inter muscular groove brachial plexus block is a commonly used peripheral nerve block technique in clinical practice, commonly used for anesthesia and analgesia in clavicle, shoulder, and humeral surgeries. The classic ultrasound-guided intermuscular groove block also involves puncturing the needle to the level of the C5\u002FC6 anterior branch for drug injection. After injection, local anesthetics mainly wrap around C5, C6, and some C7 nerve roots. Therefore, intermuscular groove block is mainly used for shoulder, humerus, and clavicle surgery. Due to incomplete ulnar block, it is not recommended for surgery on the elbow joint and its distal end.Scholars have found that using C5 as the puncture target to implement intermuscular groove block and administering 10ml of 0.75% ropivacaine, the success rate of ulnar nerve block is 19%. The success rate of ulnar nerve block with C6 as the puncture target was 93% when 10ml of 0.75% ropivacaine was administered. This suggests that blockade methods closer to the tail muscle groove on the tail side have a higher success rate for blocking the C7, C8, and T1 nerve roots. In our clinical work, the investigators found that when performing intermuscular groove block with C7 nerve root as the puncture target, local anesthetics not only stably wrap around C7 nerve root, but also spread to wrap around C5 and C6 nerve roots on the head side, and spread to the deep surface of the brachial plexus trunk on the tail side. Local anesthetic diffusion can also be seen in some patients at the brachial plexus bundle in the intercostal space. From the perspective of local anesthetic diffusion patterns, intermuscular groove block targeting the C7 nerve root may cover the anterior branches of C5, C6, C7, C8, and T1 nerve roots, achieving complete brachial plexus block. Preliminary clinical practice suggests that C7 intermuscular groove block can be used for forearm and hand surgery. Successful C7 intermuscular groove block relies on the diffusion and wrapping of local anesthetics around the anterior branches of C5, C6, and C7 nerve roots, as well as the inferior trunk of the brachial plexus (or the anterior branches of C8 and T1 nerve roots).Therefore, the investigators designed this study to determine the amount of local anesthetic required to achieve stable forearm and hand block during C7 intermuscular groove block.",[217,218],"Hand and Forearm Trauma","Hand and Forearm Diseases",[220,221,222],"ultrasound-guided interscalene block","Minimum effective dose","C7 nerve root","2026-03-30",{"date":225,"type":35},"2026-04-03",{"date":227,"type":21},"2026-04-01",{"date":229,"type":21},"2027-06-30",{"name":41,"class":42},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":43},"100516686","exploring-of-serum-biomarkers-of-delirium-after-cardiovascular-surgery-100516686","NCT06007755","Exploring of Serum Biomarkers of Delirium After Cardiovascular Surgery","Inclusion Criteria:\n\npatients who receive cardiovascular surgery\n\n* Patients participated voluntarily and signed informed consent\n\nExclusion Criteria:\n\n* past medical history of neurological and psychiatric diseases; severe visual or hearing impairment;",{"count":238,"type":21},113,"The incidence of postoperative delirium in patients after cardiovascular surgery is very high, which seriously affects the short-term and long-term prognosis of patients, but its mechanism is not clear. Recent studies have found that lactic acid participates in the process of sepsis by inducing histone lactatation in macrophages. histone H3 lysine 18 lactylation (H3K18la) is significantly associated with the severity of disease and inflammatory response. Inflammation plays an important role in postoperative delirium. We therefore hypothesized that macrophage H3K18la also plays a role in postoperative delirium. At the same time, the latest literature shows that the early markers of Alzheimer's disease (AD), such as Aβ, exosomes and phosphorylated tau, etc. \\[5\\], can also be detected in the serum of AD patients. Given the obvious correlation between Alzheimer's disease and postoperative delirium \\[6\\], we hypothesized that serum biomarkers of AD could also be used as serum biomarkers for postoperative delirium.\n\nThe objectives of this study were to investigate the correlation between H3K18 in serum monocytes and postoperative delirium and its severity in patients undergoing cardiovascular surgery. Meanwhile, we also detect the serum levels of biomarkers of AD, such as Aβ, tau and exosomes etc., in patients undergoing major cardiac surgery. We aim to find the serum biomarkers of delirium after major cardiac surgery, so as to provide a more convenient diagnostic basis for the prevention of postoperative delirium.",[241],"Delirium",[243,244,245,246,247,248,249],"delirium","biomarker","cardiovascular surgery","H3K18la","exosome","phospho-tau","Aβ",{"date":225,"type":35},{"date":252,"type":35},"2023-09-01",{"date":254,"type":21},"2027-12",{"name":41,"class":42},{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":275,"locationsCount":276},"100487823","comparison-of-an-acceleromyography--and-electromyography-based-neuromuscular-monitor-with-tof-watch--monitor-100487823","NCT05632107","Comparison of an Acceleromyography- and Electromyography-based Neuromuscular Monitor With TOF-Watch ® Monitor","Comparison of an Acceleromyography- and Electromyography-based Neuromuscular Monitor With TOF-Watch ® Monitor：a Pilot Study","Inclusion Criteria:\n\n* Age less than 18 yr\n* American Society of Anesthesiologists Physical Status I to III\n* Elective surgery requiring muscle relaxation\n* Patients participated voluntarily and signed informed consent\n\nExclusion Criteria:\n\n* Patients with known neuromuscular disorder\n* Stroke\n* Patients with a history of allergic reaction toneuromuscular blocking agents\n* Use of medications that might interfere with neuromuscular transmission\n* Any previous injury to the examined arm that might influence nerve conduction parameters\n* Pacemaker","90 Years",{"count":265,"type":21},100,"A quantitative neuromuscular monitoring device is desirable to titrate the depth of neuromuscular block (NMB) during a procedure, and to prevent residual effects after removal of the endotracheal tube. Unfortunately, the most widely used monitoring technique acceleromyography (AMG) typically implies a series of cumbersome installation and calibration procedures that frequently precludes correct use of these devices in clinical practice. Electromyography (EMG) has recently attracted a lot of attention as an alternative strategy to compensate for the deficiency of AMG-based neuromuscular monitors. Nowadays, a new technology that allows for the simultaneous acquisition of EMG and AMG signals is commercially available. Although its reliability has been rapidly accepted in Physical Medicine and Rehabilitation, the use of the technique in neuromuscular monitoring has never been reported. The aim of the present study is to assess the validity of the new device for estimating the neuromuscular block by comparing with TOF Watch®-SX, which is the most widely accepted AMG-based neuromuscular monitor that has been practiced in the clinical arena for decades.",[268],"Neuromuscular Blockade",[270],"neuromuscular blocking agents; residual neuromuscular blockade; neuromuscular monitoring; acceleromyography; electromyography",{"date":225,"type":35},{"date":273,"type":35},"2023-03-01",{"date":254,"type":21},{"name":41,"class":42},2,{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":293,"locationsCount":43},"100426404","perioperative-eeg-monitoring-and-postoperative-delirium-in-patients-undergoing-cardiovascular-surgery-100426404","NCT04832568","Perioperative EEG-Monitoring and Postoperative Delirium in Patients Undergoing Cardiovascular Surgery","Perioperative EEG-Monitoring and Postoperative Delirium in Patients Undergoing Cardiovascular Surgery: a Prospective Observational Study","Inclusion Criteria:\n\n1. age of at least 18 years\n2. normal cognitive function at the time of enrollment evidenced by a Mini-Mental State Examination (MMSE) score of more than 24 of 30\n3. Chinese Mandarin as the native language\n4. providing informed consent\n\nExclusion Criteria:\n\n1. pre-existing delirium assessed according to the Confusion Assessment Method (CAM)\n2. history of neurological or psychiatric disease\n3. impaired vision or auditory function which may effect the assessments\n4. unwillingness to participate in the study",{"count":285,"type":21},200,"Postoperative delirium is common in patients undergoing cardiovascular surgery and associated with poor outcomes. However the pathogenesis of postoperative delirium is poorly understood. Multichannel electroencephalogram is a recognized tool for identifying neurophysiologic states during anesthesia, sleep, and arousal. The aim of the current study is to evaluate the mechanisms and predictors of postoperative delirium in patients undergoing cardiovascular surgery using electroencephalogram.",[241],{"date":289,"type":35},"2026-03-31",{"date":291,"type":35},"2021-06-17",{"date":254,"type":21},{"name":41,"class":42},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":309,"locationsCount":43},"100369544","perioperative-eeg-monitoring-and-emergence-delirium-in-children-100369544","NCT04091724","Perioperative EEG-Monitoring and Emergence Delirium in Children","Perioperative EEG-Monitoring and Emergence Delirium in Children: a Prospective Observational Study","Inclusion Criteria:\n\n1. male or female children aged under 16 years\n2. planned elective surgery\n3. informed consent by parents or legal guardians\n\nExclusion Criteria:\n\n1. history of neurological or psychiatric disease\n2. delayed development\n3. inability of the parents or legal guardians to speak or read Chinese\n4. participation in another prospective interventional clinical study during this study","16 Years",{"count":137,"type":21},"Emergence delirium is a significant problem, particularly in children. However the incidence, preventative strategies, and management of emergence delirium remain unclear. Multichannel electroencephalogram is a recognized tool for identifying neurophysiologic states during anesthesia, sleep, and arousal. The aim of the current study is to evaluate the mechanisms and predictors of emergence delirium in children under 16 years scheduled for elective surgery using electroencephalogram. The \"Pediatric Anesthesia Emergence Delirium Scores (PAED Score)\" (Sikich et al. 2004) is used to screen for the occurrence of emergence delirium in the post anesthesia care unit.",[241],{"date":289,"type":35},{"date":307,"type":35},"2019-12-02",{"date":254,"type":21},{"name":41,"class":42},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":107,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":328,"leadSponsor":330,"locationsCount":4},"100631541","phase-4-a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-sox-following-heterogeneous-radiotherapy-as-first-line-treatment-for-unresectable-locally-advanced-or-metastatic-her2-negative-gastric-or-gastroesophageal-junction-adenocarcinoma-100631541","NCT07502027","A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma","A Multicenter, Single-arm, Exploratory Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Age 18-75 years, male or female.\n* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.\n* Patients with no prior systemic therapy for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. For patients who received neoadjuvant or adjuvant chemotherapy or chemoradiotherapy with curative intent, the interval from the last treatment to disease progression must be at least 6 months.\n* HER-2 negative (IHC 1+ or IHC 2+\u002FFISH-negative).\n* Presence of radiation-eligible tumor lesions.\n* No anticipated need for tumor resection during the study treatment period.\n* ECOG performance status 0-1.\n* At least one measurable lesion per RECIST v1.1. Lesions that have received prior radiotherapy cannot be selected as target lesions unless they are the only measurable lesions and show unequivocal progression on imaging, in which case they may be considered as target lesions.\n* Expected overall survival ≥ 3 months.\n* Adequate function of major organs.\n\nExclusion Criteria:\n\n* Presence of other histologic components confirmed by histopathology or cytology, such as squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, etc.\n* Prior treatment with any tumor immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies), immune checkpoint agonists (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40), or immune cell therapy (e.g., CAR-T cells).\n* Palliative local therapy to non-target lesions within 2 weeks before the first dose; or systemic non-specific immunomodulatory therapy (e.g., interleukin, interferon, thymosin) within 2 weeks before the first dose.\n* Clinically significant pleural effusion, pericardial effusion, or ascites requiring frequent drainage (≥ 1 time per month).\n* Known active or untreated brain metastasis, meningeal metastasis, spinal cord compression, or leptomeningeal disease. Patients with measurable lesions outside the central nervous system may be eligible if: they are asymptomatic after treatment, radiologically stable for at least 4 weeks before study treatment (no new or enlarging brain metastases), and have discontinued systemic corticosteroids and anticonvulsants for at least 2 weeks.\n* Gastrointestinal perforation, gastrointestinal fistula, or intra-abdominal abscess within 6 months before the first dose.\n* Clinically significant bleeding or definite bleeding diathesis within 6 months before the first dose, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, or vasculitis, excluding asymptomatic positive fecal occult blood.\n* Arterial or venous thromboembolism within 6 months before the first dose, including cerebrovascular accident (transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, pulmonary embolism, etc. Superficial venous thrombosis is permitted.\n* Clinically active hemoptysis or active diverticulitis.\n* Major surgery other than for gastric cancer diagnosis within 28 days before the first dose, or anticipated major surgery during the study period.\n* Severe infection (CTCAE grade \\> 2) within 4 weeks before the first dose, such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; active lung inflammation on baseline chest imaging; or signs\u002Fsymptoms of infection or oral\u002Fintravenous antibiotic therapy within 14 days before the first dose, excluding prophylactic antibiotics.\n* Any active or history of autoimmune disease, including but not limited to: interstitial lung disease, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism. Hypothyroidism may be allowed if controlled by hormone replacement. Patients with fully resolved psoriasis or childhood asthma\u002Fallergies requiring no intervention in adulthood may be included; those requiring medical intervention with bronchodilators are excluded.\n* History of immunodeficiency, including positive HIV test, other acquired or congenital immunodeficiency diseases, organ transplantation, or allogeneic bone marrow transplantation.\n* Uncontrolled cardiac conditions, including but not limited to:\n\n  1. NYHA class ≥ II heart failure;\n  2. unstable angina;\n  3. myocardial infarction within 1 year;\n  4. clinically significant supraventricular or ventricular arrhythmia uncontrolled or poorly controlled despite intervention;\n  5. QTc \\> 450 ms (male); QTc \\> 470 ms (female).\n* Active tuberculosis confirmed by medical history or CT scan, active tuberculosis within 1 year before screening, or history of active tuberculosis \\> 1 year without standard treatment.\n* Active hepatitis: HBsAg positive with HBV DNA ≥ 2000 IU\u002FmL; HCV antibody positive with HCV viral load above the upper limit of normal.\n* Diagnosis of another malignancy within 5 years before the first dose, except malignancies with low risk of metastasis or death (5-year survival \\> 90%), such as adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n* Administration of live attenuated vaccine within 4 weeks before the first dose. If enrolled, patients must not receive live vaccines during the study or within 120 days after the last dose of iparomlimab and tuvonralimab.\n* Known hypersensitivity or intolerance to any study drug(s) and\u002For their components.\n* Toxicity from prior anti-tumor therapy that has not resolved to NCI-CTCAE v5.0 grade 0 or 1, or to the level specified in the inclusion\u002Fexclusion criteria, except alopecia or pigmentation.\n* Pregnant or lactating female.\n* Participation in another clinical study, unless it is an observational, non-interventional study or the follow-up period of an interventional study.\n* Any other conditions judged by the investigator that may result in premature discontinuation from the study, including other severe diseases (including psychiatric disorders) requiring concurrent treatment, alcoholism, drug abuse, family or social factors that may affect patient safety or compliance.",{"count":318,"type":21},55,[24],"This study is a domestic, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of heterogeneous radiotherapy (high and low dose) sequenced with iparomlimab and tuvonralimab plus SOX as a first-line treatment for unresectable locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.",[322,323,324],"Gastric Cancer (Diagnosis)","Gastric Cancer (GC)","Gastroesophageal Junction Adenocarcinoma","2026-03-24",{"date":223,"type":35},{"date":91,"type":21},{"date":329,"type":21},"2029-06-30",{"name":41,"class":42},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":107,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":4},"100631540","phase-2-a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-fruquintinib-and-heterogeneous-radiotherapy-versus-fruquintinib-as-third-line-and-subsequent-line-treatment-for-metastatic-colorectal-cancer-100631540","NCT07502014","A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer","A Randomized, Parallel, Open-Label, Multicenter Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* Patients aged 18 to 75 years (inclusive).\n* Histologically or cytologically confirmed stage Ⅳ primary colorectal cancer.\n* No more than 5 oligometastatic lesions, with metastases usually limited to one or a few specific organs (e.g., liver, lung, etc.), and the metastatic lesions are deemed suitable for stereotactic body radiation therapy (SBRT) by the investigator.\n* Failure of at least 2 prior lines of standard therapy (based on fluorouracil, oxaliplatin, irinotecan, bevacizumab, cetuximab).\n\nNote: Adjuvant\u002Fneoadjuvant therapy is permitted. If recurrence occurs during adjuvant\u002Fneoadjuvant therapy or within 6 months after its completion, the adjuvant\u002Fneoadjuvant therapy will be regarded as the first-line therapy for advanced disease.\n\n* At least one extracranial measurable lesion meeting the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\n* Prior radiotherapy is permitted, but it must be more than 4 weeks before study enrollment. In addition, the lesions selected for radiotherapy and evaluable lesions in this study must be untreated with radiotherapy, and the prior radiotherapy must not affect the normal tissue dose of radiotherapy in this study. (Note: If radiotherapy was received before enrollment, detailed radiotherapy-related parameter data must be provided.)\n* If a subject has undergone surgery, he\u002Fshe must have fully recovered from the toxicities and complications of the surgical intervention before the start of treatment, and enrollment will be considered only after the wound is completely healed.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.\n* Expected survival of ≥12 weeks.\n* Adequate function of major organs (no use of any blood components or cell growth factors within 2 weeks before enrollment), meeting the following requirements:\n\n  1. Bone marrow function: Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL, white blood cell (WBC) count ≥4.0×10⁹\u002FL, platelet count ≥100×10⁹\u002FL, hemoglobin (Hb) ≥90 g\u002FL.\n  2. Hepatic function: Serum total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN). If serum total bilirubin level \\>1.5×ULN, direct bilirubin level must be ≤ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (up to 5×ULN for patients with liver metastases).\n  3. Renal function: Blood urea nitrogen (BUN) and serum creatinine (Cr) ≤1.5×ULN (with creatinine clearance rate (CCr) ≥50 mL\u002Fmin).\n  4. Cardiac function: Normal cardiac function with left ventricular ejection fraction (LVEF) ≥50%.\n  5. Coagulation function: International normalized ratio (INR) ≤1.5×ULN, activated partial thromboplastin time (APTT) ≤1.5×ULN.\n* Male or female patients of childbearing potential must voluntarily use effective contraceptive methods during the study and within 6 months after the last study drug administration, such as double barrier contraception, condoms, oral or injectable contraceptives, intrauterine devices, etc. All female patients will be considered of childbearing potential unless they have natural menopause, artificial menopause, or sterilization (e.g., hysterectomy, bilateral adnexectomy, ovarian irradiation, etc.).\n\nExclusion Criteria:\n\n* Prior treatment with anti-PD-1\u002FPD-L1, anti-CTLA-4 agents, or other investigational immunotherapeutic agents.\n* Severe autoimmune diseases, including active inflammatory bowel disease (Crohn's disease, ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, autoimmune vasculitis (e.g., Wegener's granulomatosis), etc.\n* Symptomatic interstitial lung disease or active infectious\u002Fnon-infectious pneumonitis.\n* Risk factors for intestinal perforation: active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, abdominal cancer, or other known risk factors for intestinal perforation.\n* History of other malignancies; however, patients with cured localized tumors such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, cervix, or breast may be enrolled.\n* Patients planning to undergo or having previously received organ or allogeneic bone marrow transplantation.\n* Clinically significant moderate to severe ascites requiring therapeutic paracentesis or drainage, or Child-Pugh score \\>2 (except for radiologically detected minimal ascites without clinical symptoms); uncontrolled moderate or large pleural effusion or pericardial effusion.\n* History of gastrointestinal bleeding or definite bleeding tendency within 6 months prior to initiation of study treatment, including: high-risk or severe esophagogastric varices, active local peptic ulcer lesions, persistent positive fecal occult blood test. (Patients with positive baseline fecal occult blood may be retested; if still positive, esophagogastroduodenoscopy (EGD) is required. Patients with EGD evidence of bleeding-risk varices are excluded.)\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to initiation of study treatment.\n* Known congenital or acquired bleeding disorders (e.g., coagulopathy) or thrombotic tendency such as hemophilia; currently using or having recently used (within 10 days before study treatment) full-dose oral or injectable anticoagulants or thrombolytic agents for therapeutic purposes. (Prophylactic use of low-dose aspirin or low-molecular-weight heparin is permitted.)\n* Currently using or having recently used (within 10 days before study treatment) aspirin (\\> 325 mg\u002Fday, maximal antiplatelet dose), dipyridamole, ticlopidine, clopidogrel (≥75 mg), or cilostazol.\n* Thrombotic or embolic events within 6 months prior to initiation of study treatment, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), pulmonary embolism, etc.\n* Active infection, heart failure, myocardial infarction within 6 months, unstable angina, or uncontrolled arrhythmia.\n* Any physical or clinical laboratory abnormality that, in the investigator's opinion, may interfere with study outcomes or increase the risk of treatment complications, or other uncontrolled medical conditions.\n* Patients requiring urgent palliative radiotherapy or emergency surgery (spinal cord compression, cerebral herniation, pathological fracture) as judged by the investigator.\n* Breastfeeding or pregnant female patients.\n* Congenital or acquired immunodeficiency disorders including human immunodeficiency virus (HIV) infection, or history of organ transplantation or allogeneic stem cell transplantation.\n* Patients with psychiatric disorders, substance abuse, or social issues affecting compliance, as determined by the treating physician.\n* Active infection including active tuberculosis is excluded. Patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection may be enrolled if disease is stable following antiviral therapy.\n* Administration of live attenuated vaccines within 30 days prior to enrollment. (Note: Injectable seasonal influenza vaccines are mostly inactivated and permitted; intranasal formulations are usually live attenuated and prohibited.)\n* Poorly controlled cardiac symptoms or diseases including:\n\n  1. New York Heart Association (NYHA) Class ≥II cardiac insufficiency or LVEF \\\u003C50% on echocardiography;\n  2. Unstable angina;\n  3. Myocardial infarction within 1 year prior to initiation of study treatment;\n  4. Clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention;\n  5. QTc interval \\>450 ms (males) or \\>470 ms (females) calculated by Fridericia formula. (If QTc is abnormal, three consecutive measurements at 2-minute intervals may be performed and averaged.)\n* Hypertension not adequately controlled by antihypertensive therapy (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, based on average of ≥2 measurements). History of hypertensive crisis or hypertensive encephalopathy.\n* Major vascular disease within 6 months prior to initiation of study treatment (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis).\n* Severe, non-healing or dehiscent wound, active ulcer, or untreated fracture.\n* Major surgery (except diagnostic procedures) within 4 weeks prior to initiation of study treatment, or expected major surgery during the study period.\n* Inability to swallow tablets, malabsorption syndrome, or any condition impairing gastrointestinal absorption.\n* History of intestinal obstruction or clinical signs\u002Fsymptoms of gastrointestinal obstruction within 6 months prior to initiation of study treatment, including partial obstruction related to underlying disease requiring parenteral hydration, parenteral nutrition, or tube feeding.\n* Patients presenting with partial obstruction, obstruction syndrome, or signs\u002Fsymptoms of ileus at initial diagnosis may be enrolled if they received definitive (surgical) treatment resulting in resolution of symptoms.\n* Evidence of intra-abdominal free air not explained by recent paracentesis or surgery.\n* Metastatic disease involving major airways or vessels (e.g., complete occlusion of main portal vein or vena cava due to tumor invasion is excluded; main portal vein is defined as the confluence of splenic and superior mesenteric veins and its bifurcation into right and left intrahepatic branches) or large central mediastinal mass (\\\u003C30 mm from carina).\n* History of hepatic encephalopathy.\n* Current interstitial pneumonitis or interstitial lung disease; history of interstitial pneumonitis or lung disease requiring corticosteroid treatment; pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), pneumoconiosis, drug-related pneumonitis, idiopathic pneumonia, or evidence of active pneumonitis on screening chest CT with severely impaired pulmonary function. (History of radiation pneumonitis in radiation field is permitted.) Active tuberculosis.\n* Active autoimmune disease or history of autoimmune disease with potential recurrence (including but not limited to autoimmune hepatitis, interstitial lung disease, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism). Patients with controlled hypothyroidism requiring only hormone replacement may be enrolled. Patients with skin diseases not requiring systemic therapy (vitiligo, psoriasis, alopecia), controlled type 1 diabetes mellitus on insulin, or childhood asthma in complete remission without adult intervention may be enrolled. Asthma requiring medical intervention with bronchodilators is excluded.\n* Use of immunosuppressive agents or systemic corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) for immunosuppressive purposes within 14 days prior to initiation of study treatment.\n* Known severe hypersensitivity to any monoclonal antibody or anti-angiogenic targeted therapy.\n* Seere infection within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for infection, bacteremia, or severe pneumonia; therapeutic oral or intravenous antibiotics within 2 weeks prior to initiation of study treatment. (Patients receiving prophylactic antibiotics are eligible.)\n* Patients with any other conditions that, in the investigator's judgment, may affect study outcomes or lead to premature discontinuation, such as alcoholism, drug abuse, other severe comorbidities (including psychiatric disorders), significant laboratory abnormalities, or family\u002Fsocial issues compromising patient safety, will be excluded.",{"count":339,"type":21},60,[111],"This is a randomized, parallel, open-label, multicenter exploratory clinical study designed to investigate the efficacy and safety of iparomlimab and tuvonralimab in combination with fruquintinib plus heterogeneous radiotherapy, compared with fruquintinib monotherapy, as the third-line and subsequent-line treatment for patients with oligometastatic colorectal cancer.",[343,344],"Metastatic Colorectal Cancer (CRC)","mCRC",{"date":223,"type":35},{"date":347,"type":21},"2026-05-01",{"date":349,"type":21},"2029-12-31",{"name":41,"class":42},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":158,"enrollmentInfo":358,"targetDuration":360,"studyType":193,"phases":4,"briefSummary":361,"conditions":362,"keywords":365,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":43},"100624520","correlating-eeg-dynamics-with-consciousness-alteration-under-anesthesia-100624520","NCT07410702","Correlating EEG Dynamics With Consciousness Alteration Under Anesthesia","EEG Signatures of Unconsciousness Induced by Anesthetic Agents and Their Dynamics Across the Consciousness Continuum","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Scheduled to undergo elective surgery requiring general anesthesia with endotracheal intubation or laryngeal mask airway (LMA).\n3. American Society of Anesthesiologists (ASA) Physical Status Class I to III.\n4. Preoperative Mini-Mental State Examination (MMSE) score ≥ 24, indicating normal cognitive function.\n5. Body mass index (BMI) ≤ 30 kg\u002Fm².\n6. Ability to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. History of drug abuse or dependence.\n2. Known major neurological disorders (e.g., epilepsy, stroke, neurodegenerative diseases).\n3. History of major psychiatric disorders.\n4. Known or suspected pregnancy.\n5. Inability to provide informed consent due to cognitive impairment, language barrier, or any other reason.",{"count":359,"type":21},250,"1 Day","This prospective observational study is designed to investigate and compare the dynamic features of whole-brain electroencephalogram (EEG) during the induction of unconsciousness using various anesthetic agents with distinct pharmacological mechanisms. The primary objective is to identify common, drug-agnostic EEG biomarkers of anesthetic depth and to develop a novel, universal assessment system that addresses the limitations of the currently prevalent Bispectral Index (BIS), which demonstrates variable sensitivity across different anesthetics.\n\nApproximately 250 adult patients (ASA I-II) scheduled for elective surgery under general anesthesia will be enrolled. Patients will undergo preoperative cognitive assessment prior to induction. During anesthesia induction, 32-channel EEG signals will be continuously recorded alongside BIS values and behavioral state assessments using the MOAA\u002FS scale as the reference standard.\n\nPatients will receive one of the following intravenous anesthetics for induction: Propofol, Ciprofol, Remimazolam, Esketamine, or Fospropofol. Features will be extracted from the preprocessed EEG data. Statistical analyses will compare these features across drug groups and in relation to behavioral state transitions. Machine learning models (e.g., Random Forest) will then be trained to classify states of consciousness based on the extracted EEG features, with model performance validated against the behavioral gold standard.\n\nThe study aims to establish a more robust and generalizable neurophysiological framework for monitoring anesthetic depth, potentially improving the precision and safety of clinical anesthesia management.",[363,364],"Altered State of Consciousness","General Anesthetics",[364,366,367,368],"Electroencephalography","Neural correlates of consciousness","Consciousness monitoring","2026-03-22",{"date":325,"type":35},{"date":372,"type":35},"2026-02-10",{"date":374,"type":21},"2027-02-20",{"name":41,"class":42},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":51,"minAge":53,"maxAge":135,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":4},"100610622","clinical-efficacy-of-thumbtack-needle-for-chronic-insomnia-in-perimenopausal-and-menopausal-women-100610622","NCT07229976","Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women","Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women: A Multicenter Randomized Controlled Trial","Diagnostic criteria for perimenopause and menopause:\n\n* Perimenopausal period: a period of time from one year before the last menstrual period to the first year after the last menstrual period. Having at least one menstrual period in the past 12 months, or being under 55 years old, undergoing hysterectomy or endometrial ablation, but not bilateral oophorectomy;\n* Menopause: No menstruation in the past 12 months, or bilateral oophorectomy, or age 55 years or older, who has undergone hysterectomy or endometrial ablation;\n\nDiagnostic criteria for chronic insomnia:\n\n●The diagnostic criteria for insomnia in the third edition of the International Classification of Sleep Disorders (ICSD-3) of the American Academy of Sleep Medicine (all criteria A to F must be met).\n\nInclusion Criteria:\n\n* Women aged 40 to 65 who meet the diagnostic criteria for perimenopause and menopause mentioned above;\n* Evaluate ISI score ≥ 12 points through a scale;\n* Meets the diagnostic criteria for chronic insomnia mentioned above, i.e. ICSD-3 meets both criteria A to F;\n* Voluntarily participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\nPatients who meet any of the following conditions will not be included;\n\n* Use hormone replacement therapy, anti anxiety drugs, antidepressants, or medications to improve insomnia within one month;\n* Individuals with a history of diagnosed sleep disorders before menopause;\n* Combined with other sleep disorders such as obstructive sleep apnea, restless leg syndrome, etc;\n* Patients with malignant tumors, especially estrogen dependent tumors (such as breast cancer and endometrial cancer);\n* Recent (within 6 months) history of myocardial infarction, stroke, venous thrombosis, etc;\n* Patients with mental illnesses, such as severe depression and uncontrolled schizophrenia;\n* Serious disorder of endocrine system, such as uncontrolled hyperthyroidism, diabetes ketoacidosis, etc\n* Patients with coagulation disorders, such as hemophilia, long-term use of anticoagulants (warfarin, aspirin, etc.), etc;\n* Long term alcohol consumption history (more than 5 years, daily alcohol consumption exceeding 12 taels, not quitting drinking);\n* Engaged in night shift work (\\>3 times a week);\n* Individuals with infections, ulcers, burns, rashes, or scars at acupoints;\n* Previously received acupuncture treatment;\n* I do not agree to sign the informed consent form for this study.",{"count":384,"type":21},198,[57],"A multicenter, randomized, controlled, blinded clinical trial was conducted to evaluate the effects of thumbtack needle on sleep in patients with chronic insomnia during perimenopause and menopause. Randomly divided into a treatment group and a control group using the central area method, with 99 patients in each group. The treatment group received thumbtack needle treatment, while the control group received placebo thumbtack needle treatment. The treatment course for both groups was 4 weeks.",[388],"Chronic Insomnia During Perimenopause and Menopause","2026-03-15",{"date":391,"type":35},"2026-03-17",{"date":393,"type":21},"2026-03-20",{"date":395,"type":21},"2029-12-30",{"name":41,"class":42},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":404,"sex":16,"minAge":77,"maxAge":107,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":416,"locationsCount":417},"100593342","effects-of-lpg-and-ventilation-interventions-on-reducing-hap-and-improving-cardiopulmonary-health-100593342","NCT07005193","Effects of LPG and Ventilation Interventions on Reducing HAP and Improving Cardiopulmonary Health","Effects of Liquefied Petroleum Gas and Ventilation Interventions on Reducing Household Air Pollution From Solid Fuel Use and Improving Cardiopulmonary Health: A Multi-center, 2×2 Factorial Randomized Controlled Trial","1. Inclusion Criteria Primary Participants：\n\n   * Aged 18-75 years;\n   * Local permanent residents with no plans for long-term travel or relocation within one year;\n   * Kitchen suitable for installation of ventilation facilities;\n   * Responsible for daily household cooking, cooking ≥5 times per week;\n   * To control for community penetration of pollution, households will be preferentially recruited in naturally ventilated, open villages, avoiding valleys or basins that hinder pollutant dispersion; preference for detached houses with ≥10 m distance from neighboring kitchens and well-sealed doors and windows.\n\n   Secondary Participants:\n   * Elderly individuals aged 65-75 living with the primary participant;\n   * Children aged 3-6 living in the same household.\n2. Exclusion Criteria:\n\n   * Clinical diagnosis of major chronic diseases such as severe respiratory diseases, cardiovascular diseases, malignant tumors, or end-stage renal disease;\n   * Pregnant or breastfeeding women;\n   * Current smokers or individuals with self-reported exposure to productive dust or other occupational hazards;\n   * Individuals who are unable to fully understand the study process or clearly express their own complaints, such as those with psychiatric disorders or severe neuroses, or who cannot cooperate with the study for other reasons.",true,{"count":406,"type":21},1200,[57],"The goal of this clinical trial is to evaluate the independent and synergistic effects of liquefied petroleum gas (LPG) substitution and improved ventilation on household air pollution (HAP) reduction and cardiopulmonary health. The main questions it aims to answer are:\n\n1. Does LPG substitution or improved ventilation reduce HAP and improve cardiopulmonary health?\n2. Would the combined intervention of LPG substitution and improved ventilation outperform single interventions?\n3. What is the cost-effectiveness of such interventions, and are they sustainable?\n4. Does the intervention reduce the incidence of cardiopulmonary clinical events?\n\nParticipants will be randomized in 4 groups:\n\nA: Solid fuel + no ventilation facilities group (300 households): Continued use of solid fuels without installation of ventilation facilities and receipt of standardized health education. No LPG stoves or ventilation equipment will be provided during the intervention period. However, after the primary endpoint assessment at 12 months, all households in Group A will be provided with LPG stoves and ventilation facilities of equivalent specifications free of charge, along with health guidance. Phased cash compensation will be provided during the intervention period.\n\nB: Liquefied petroleum gas (LPG) + no ventilation facilities group (300 households): Provided with LPG stoves and instructed to use them during cooking, with regular LPG supply throughout the intervention period. Participants will also receive standardized health education.\n\nC: Solid fuel + ventilation facilities group (300 households): Continued use of solid fuels while being provided with ventilation facilities and instructed to use them during cooking. Electricity costs will be compensated during the intervention period. Participants will also receive standardized health education.\n\nD: LPG + ventilation facilities group (300 households): Provided with both LPG stoves and ventilation facilities and instructed to use both during cooking. Regular LPG supply and electricity cost compensation will be provided throughout the intervention period. Participants will also receive standardized health education.",[410,411],"Cardiopulmonary Function","Environmental Exposures",{"date":391,"type":35},{"date":414,"type":35},"2025-07-01",{"date":329,"type":21},{"name":41,"class":42},3,{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":211,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":428,"conditions":429,"keywords":433,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":43},"100559575","phase-4-bupivacaine-liposome-plus-bupivacaine-or-ropivacaine-for-pericapsular-nerve-group-block-in-hip-arthroplasty-peng-100559575","NCT06565910","Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)","Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for PENG Block on Post Operative Pain Management in Patients Undergoing Hip Arthroplasty: a Prospective, Randomized, Single Blind, Active Controlled Study","PENG","Inclusion Criteria:\n\n* American Society of Anesthesiologists(ASA) I\\~II\n* Normal coagulation\n* Clinical diagnosis of hip fracture\n\nExclusion Criteria:\n\n* Presence of severe systemic diseases or ASA grade III or higher\n* Allergy to amide local anesthetics",{"count":339,"type":21},[24],"The goal of this clinical trial is to study the analgesic effect of liposomal bupivacaine plus bupivacaine for Pericapsular Nerve Group (PENG) block in postoperative pain management following hip replacement surgery. It will also assess the safety of liposomal bupivacaine for this purpose. The main questions it aims to answer are:\n\n1. Is liposomal bupivacaine plus bupivacaine superior to ropivacaine in terms of analgesic efficacy, duration of pain relief, opioid consumption, and patient satisfaction?\n2. What medical problems do participants encounter when using liposomal bupivacaine plus bupivacaine for PENG block in postoperative pain management following hip replacement surgery?\n\nResearchers will compare liposomal bupivacaine plus bupivacaine to ropivacaine (a routinely used regional anesthetic in clinical practice) to determine if liposomal bupivacaine plus bupivacaine is more effective for pain management following hip replacement surgery.\n\nParticipants will:\n\n1. Receive liposomal bupivacaine plus bupivacaine or ropivacaine as a regional anesthetic for PENG block under ultrasound guidance.\n2. Undergo hip replacement surgery under spinal anesthesia.\n3. Have pain relief, opioid analgesic consumption, and incidence of complications assessed at multiple time points within 72 hours after surgery.",[430,431,432],"Femoral Neck Fractures","Femur Head Necrosis","Hip Fractures",[434,435,436,437],"Bupivacaine Liposome","PENG block","Hip Arthroplasty","Randomized Controlled Trial","2026-03-11",{"date":440,"type":35},"2026-03-13",{"date":442,"type":35},"2024-12-04",{"date":444,"type":21},"2026-07-01",{"name":41,"class":42},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":51,"minAge":453,"maxAge":53,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":43},"100403438","effect-of-acupuncture-on-ivf-pregnancy-outcomes-for-women-with-rif-100403438","NCT04533295","Effect of Acupuncture on IVF Pregnancy Outcomes for Women With RIF","Effect of Acupuncture on IVF Pregnancy Outcomes for Women With Recurrent Implantation Failure: a Multi-center Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Married women aged 25-40;\n2. Repeated implantation failure for unknown reasons (experienced 2 or more embryo transfers of good-quality embryos without achieving clinical pregnancy);\n3. Transplantable Day 3 high-quality frozen embryos or frozen blastocysts (≥3BB);\n4. Estrogen and progesterone replacement therapy (HRT), endometrial thickness ≥7mm on the day of endometrial transformation.\n\nExclusion Criteria:\n\nPatients who met any of the following conditions were not included.\n\n1. Those who prepare for PGD;\n2. Recipients of egg donors;\n3. Chromosomal abnormalities in both or one of the couples (excluding chromosome polymorphism);\n4. patients with implantation failure due to known embryonic factors;\n5. Uterine lesions that may affect implantation (including uterine malformation, \\>4cm intramural fibroids，submucosal fibroids, adenomyosis, uterine tuberculosis, intrauterine adhesions, etc.\n6. Repeated spontaneous abortion (2 or more fetal loss before 28 weeks of gestation);\n7. Patients with other endocrine diseases, such as thyroid disease, hyperprolactinemia, insulin resistance, diabetes, adrenal disease, etc., and poor control of hormone levels in the last 3 months;\n8. Clearly diagnosed autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, etc.;\n9. Hydrosalpinx untreated;\n10. BMI less than 18 or higher than 25kg\u002Fm2;\n11. People with previous history of needle sickness;\n12. Those who have previously participated in this study or received acupuncture treatment in the past 3 months.\n13. Any situation that researchers consider inappropriate for participating in this study.","25 Years",{"count":455,"type":21},771,[57],"The randomized, placebo-controlled multicenter trial is conducted in five centers in China. After screening and obtaining the signed informed consent , the participants are randomly divided into three groups: acupuncture group (Acu.+IVF），sham acupuncture group（Sham Acu. +IVF），and the control group (only IVF).",[459],"Repeated Implantation Failure","2026-03-08",{"date":462,"type":35},"2026-03-10",{"date":464,"type":35},"2020-11-02",{"date":466,"type":21},"2027-09-01",{"name":41,"class":42},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":477,"conditions":478,"keywords":485,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":498,"locationsCount":276},"100628610","management-of-pancreatic-cystic-lesions-using-artificial-intelligence-based-on-eus-and-multimodal-data-100628610","NCT07463872","Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data","A Multimodal Artificial Intelligence Model for Subtyping Diagnosis and Clinical Management of Pancreatic Cystic Lesions Based on Endoscopic Ultrasound and Clinical Information","Inclusion criteria:\n\n* Patients whose EUS results indicates pancreatic cystic or cystoid lesions;\n* Mucinous lesions: including mucinous cystic neoplasm (MCN), intraductal papillary mucinous neoplasm (IPMN);\n* Non-mucinous lesions: including pancreatic pseudocyst, serous cystic neoplasm (SCN), cystic neuroendocrine tumor (cNET).\n\nExclusion criteria:\n\n* Patients whose age is less than 18 years old;\n* Patients who have undergone pancreatic surgery before the EUS examination;\n* Patients who have received chemotherapy and radiotherapy for pancreatic tumors before the EUS examination;\n* Pathological results indicate that pancreatic lesions are metastatic lesions from other sites;\n* Patients whose EUS images or reports are missing;\n* EUS image quality does not meet the requirements for review, such as blurry imaging or containing artifacts, biopsy needles, measuring scales, or other additional annotations that are not part of the original EUS image;\n* Patients whose final diagnosis is unclear.",{"count":476,"type":21},500,"The primary objective is to construct a multimodal AI model (Cyst-AI) based on EUS images and clinical data such as imaging features(CT or MRI) and laboratory tests to assist endoscopists in the diagnosis of pancreatic cystic lesions(PCLs), mainly differentiating mucinous from non-mucinous lesions.\n\nThe secondary objective is to evaluate the model's effectiveness in risk stratification and clinical management for patients with PCLs.",[479,480,481,482,483,484],"Pancreatic Cystic Lesion","Mucinous Cystadenoma of Pancreas","Intraductal Papillary Mucinous Neoplasm of Pancreas","Pseudocyst Pancreas","Serous Cystadenoma","Neuroendocrine Tumors, NET",[486,487,488,489,490,491,492],"pancreatic cystic lesions","artificial intelligence","endoscopic ultrasound","multimodal","differentiation","risk stratification","clinical management","2026-03-05",{"date":438,"type":35},{"date":496,"type":35},"2025-01-01",{"date":95,"type":21},{"name":41,"class":42},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":506,"enrollmentInfo":507,"targetDuration":509,"studyType":193,"phases":4,"briefSummary":510,"conditions":511,"keywords":519,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":43},"100627418","eus-guided-ctcs--multi-omics-predicting-pancreatic-cancer-recurrence-and-metastases-100627418","NCT07448376","EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases","Exploratory Study on EUS-guided Portal Vein CTCs and Their Subtypes Combined With Multi-omics Detection for Early Warning of Pancreatic Cancer Recurrence and Metastasis","Inclusion Criteria:\n\n1. Patients with solid masses (diameter \\> 1 cm) in the pancreatic area within the accessible range of endoscopic ultrasound, as indicated by clinical symptoms, laboratory tests, and imaging examinations (MRI, CT, B-ultrasound), who require biopsy to clarify the nature of the lesion.\n2. Patients diagnosed with resectable pancreatic cancer, borderline resectable pancreatic cancer, locally advanced pancreatic cancer by imaging(CT\u002FMRI).\n3. Newly diagnosed pancreatic cancer patients who have not received radiotherapy or chemotherapy.\n4. Signed informed consent form.\n5. Patients must be able to comply with the trial requirements.\n\nExclusion Criteria:\n\n1. Patients with other active malignant tumors\n2. Patients with coagulation dysfunction (PLT 50,000\u002Fmm3, INR \\> 1.5; roughly estimated, INR \\> 1.5 is approximately equivalent to PT \\> 18 seconds)\n3. Pregnant women\n4. Patients with hemorrhagic diseases\n5. Patients with a history of taking anticoagulant drugs such as aspirin and warfarin in the past week\n6. Patients with absolute contraindications to EUS examination, a history of acute pancreatitis within the past 2 weeks, a history of gastric surgery, pregnancy, severe diseases, or a history of allergy to anesthetics\n7. Patients whose EUS examination was terminated early due to esophageal stenosis, obstruction, large space-occupying lesions, rapid changes in the patient's heart rate or respiratory rate, patient intolerance, or a large amount of food residue, etc.\n8. Patients with known hepatitis C virus infection\n9. Patients with known human immunodeficiency virus (HIV) infection\n10. Patients with imaging examinations, EUS results, etc., suggesting pancreatic cystic space-occupying lesions\n11. Patients who have received radiotherapy or chemotherapy\n12. Patients with incomplete pathological information, unable to make a clear diagnosis, or unable to sign the informed consent form","70 Years",{"count":508,"type":21},20,"2 Years","The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning of recurrence and metastasis of resectable pancreatic cancer(RPC) and borderline resectable pancreatic cancer (BRPC).",[512,513,514,515,516,517,518],"CTCs","Pancreatic Cancer","Liver Metastases","Relapse","Borderline Resectable Pancreatic Cancer","Resectable Pancreatic Cancers","EUS",[518,520,513,521,522,523,524],"CTC","metastases","relapse","BRPC","RPC","2026-02-25",{"date":527,"type":35},"2026-03-04",{"date":529,"type":21},"2026-03-01",{"date":531,"type":21},"2027-12-30",{"name":41,"class":42},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":211,"enrollmentInfo":539,"targetDuration":4,"studyType":22,"phases":540,"briefSummary":541,"conditions":542,"keywords":548,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":555,"leadSponsor":556,"locationsCount":4},"100624480","phase-4-bupivacaine-liposome-versus-bupivacaine-for-ultrasound-guided-suprascapular-nerve-combined-with-axillary-nerve-block-in-analgesia-after-arthroscopic-shoulder-surgery-100624480","NCT07410182","Bupivacaine Liposome Versus Bupivacaine for Ultrasound-Guided Suprascapular Nerve Combined With Axillary Nerve Block in Analgesia After Arthroscopic Shoulder Surgery","Inclusion Criteria:\n\n1. Aged 18-60 years\n2. ASA physical status I-II\n3. Undergoing unilateral arthroscopic shoulder surgery\n4. The Operative time between 1and 4 hours\n\nExclusion Criteria:\n\n1. Anticipated operative time \\\u003C 1 h or \\> 4 h\n2. Severe cardiopulmonary insufficiency\n3. Hepatic or renal dysfunction\n4. Coagulopathy\n5. Diabetic peripheral neuropathy\n6. History of nerve injury on the operative side\n7. Skin infection at the block site\n8. Allergy to amide local anesthetics\n9. Refusal to participate or any other condition deemed unsuitable.",{"count":339,"type":21},[24],"This trial is designed to compare the post-operative analgesic efficacy and safety of liposomal bupivacaine versus plain bupivacaine when both are used for ultrasound-guided combined suprascapular and axillary nerve block in patients undergoing elective arthroscopic shoulder surgery.",[543,544,545,546,547],"Arthroscopic Shoulder Surgery","Ultrasound Guided Nerve Block","Bupivacaine","Suprascapular Nerve Block","Axillary Nerve Block",[543,549,550,547],"ultrasound guided nerve block","suprascapular nerve block","2026-02-07",{"date":553,"type":35},"2026-02-13",{"date":529,"type":21},{"date":183,"type":21},{"name":41,"class":42},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":135,"enrollmentInfo":563,"targetDuration":4,"studyType":22,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":43},"100623849","the-influence-of-explainability-and-integrability-of-ai-cdss-on-usage-behavior-among-primary-care-physicians-100623849","NCT07401979","The Influence of Explainability and Integrability of AI-CDSS on Usage Behavior Among Primary Care Physicians","Inclusion Criteria:\n\n1. Be currently employed full-time in clinical practice at a primary care facility, including community health centers, community health stations, township hospitals, or village clinics;\n2. Hold a clinical medical license with a specialty in general practice or internal medicine, and have experience in diagnosing and managing respiratory tract infections;\n3. Have at least one year of clinical work experience;\n4. Be proficient in basic computer use (e.g., web browsing and online questionnaire completion), have reliable internet access, and be capable of independently completing the online experimental tasks;\n5. Provide voluntary informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Non-clinical staff (e.g., administrative personnel, pharmacists, laboratory technicians, or public health workers who do not directly provide outpatient clinical care);\n2. Individuals unable to independently complete the online experimental procedure or who demonstrate significant difficulty understanding the task instructions.",{"count":564,"type":21},3000,[57],"The goal of this observational experimental study is to determine how system-level features of artificial intelligence clinical decision support systems (AI-CDSS)-specifically explainability and integrability-affect usage behavior among primary care physicians in China. The study focuses on licensed primary care physicians, regardless of gender, age, years of clinical experience, or prior AI exposure.\n\nThe main questions it aims to answer are:\n\n* Do specific AI features (e.g., feature attribution, chain-of-thought explanation, seamless workflow integration, automated data input) independently influence physicians' adoption intention, diagnostic accuracy, and their perceptions of the system's usefulness and ease of use?\n* Do pairwise combinations of these AI features produce significant interaction effects-either synergistic or antagonistic-on these outcomes? Researchers will compare 32 distinct AI interface configurations generated from a 2⁶-¹ fractional factorial design (Resolution VI), each representing a unique combination of six binary AI features: (A) gradient-based feature importance (0 = absent, 1 = present), (B) chain-of-thought reasoning (0\u002F1), (C) workflow integration (0 = multiple pop-up alerts, 1 = unified sidebar display), (D) automated data extraction (0 = manual entry, 1 = auto-populated from case text), (E) recommendation scope adapted to primary care settings (0 = restricted to essential options, 1 = full range of recommendations), and (F) model confidence display (0 = absent, 1 = present). This design enables unbiased estimation of all six main effects and all 15 two-way interactions.\n\nParticipants will:\n\nComplete three standardized clinical case scenarios involving common respiratory infections via a web-based simulation platform; First provide an initial diagnosis and treatment plan without any AI input; Then review an AI-generated recommendation embedded with a randomly assigned combination of the six AI features; Revise their final diagnosis and prescription based on the AI suggestion; Rate their adoption intention, perceived usefulness, and perceived ease of use using validated 7-point Likert-scale items after each case.",[568],"Respiratory Tract Infections (RTI)","2026-02-03",{"date":571,"type":35},"2026-02-11",{"date":573,"type":21},"2026-02-05",{"date":575,"type":21},"2026-04-20",{"name":41,"class":42},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":584,"enrollmentInfo":585,"targetDuration":4,"studyType":22,"phases":587,"briefSummary":588,"conditions":589,"keywords":591,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":99},"100582265","effects-of-vitamin-d3-and-yeast-beta-glucan-supplementation-on-glycemic-control-and-cardiovascular-disease-risk-in-patients-with-type-2-diabetes-100582265","NCT06861062","Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes","Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes: A Randomized Double-Blind Controlled Trial","Inclusion Criteria:\n\n1. Type 2 diabetes mellitus diagnosed by a physician based on the diagnostic criteria outlined in the Guideline for the Prevention and Treatment of Diabetes Mellitus in China (2024 Edition);\n2. Men or women aged 40-79 years;\n3. Convenient access to the study centers and permanent residence in the vicinity for the next five years;\n4. Voluntary participation and signed written informed consent.\n\nExclusion Criteria:\n\n1. History of clinical cardiovascular disease (including myocardial infarction, treatment or hospitalization for heart failure, stroke, and coronary revascularization) within the past 6 months;\n2. History of severe diabetic microvascular complications (diabetic nephropathy with an estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002F(min·1.73m²), proliferative diabetic retinopathy, confirmed diabetic peripheral neuropathy with abnormal nerve conduction studies or small fiber neuropathy testing);\n3. History of cancer, excluding non-melanoma skin cancer or cancers with a favorable prognosis;\n4. History of kidney stones, hypercalcemia, or hyperparathyroidism;\n5. History of severe liver disease, severe kidney disease, severe gastrointestinal disease, severe infectious diseases, severe sarcoidosis or other granulomatous diseases, severe mental illness, or any other condition considered unsuitable for participation judged by the clinic team;\n6. Laboratory evaluation:\n\n   * Blood calcium levels greater than or equal to the normal range for the clinical site's laboratory;\n   * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels higher than 3 times the normal range for the clinical site's laboratory;\n   * eGFR \\\u003C 30 mL\u002F(min·1.73m²);\n7. Individuals currently taking vitamin D supplements (\\>400 IU\u002Fday), calcium supplements (\\>600 mg\u002Fday), yeast β-glucan supplements (\\>250 mg\u002Fday), or those with a history of allergy or intolerance to vitamin D or prebiotic products;\n8. Participation in other clinical trials within the past 3 months;\n9. Planning to become pregnant within the next five years, or currently pregnant or breastfeeding.","79 Years",{"count":586,"type":21},2500,[57],"This study is a randomized, double-blind, placebo-controlled trial involving 2,500 individuals aged 40-79 with type 2 diabetes (T2D). The trial includes a 2-year intervention period followed by a 3-year post-intervention follow-up. The primary objective is to investigate (a) the effect of daily supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) on glycemic control in patients with T2D and (b) whether daily supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) reduces the predicted 10 year risk of atherosclerotic cardiovascular disease (ASCVD) in patients with T2D. The secondary objectives include evaluating the effects of vitamin D3 or yeast β-glucan supplementation on cardiometabolic risk factors, inflammatory markers, and liver and kidney function indicators, and assessing whether such supplementation reduces the risk of cardiovascular disease, microvascular complications and mortality over the 3-year post-intervention period.",[590],"Diabetes Mellitus, Type 2",[592,593,590,594,595],"Vitamin D","yeast β-glucan","Cardiovascular Disease","glycemic control","2026-01-28",{"date":598,"type":35},"2026-02-02",{"date":600,"type":35},"2025-04-08",{"date":602,"type":21},"2032-12-31",{"name":41,"class":42},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":16,"minAge":611,"maxAge":107,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":614,"briefSummary":615,"conditions":616,"keywords":619,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":628,"locationsCount":43},"100592194","evaluation-of-urolithin-a-and-fisetin-on-improving-sleep-and-aging-biomarkers-100592194","NCT06990256","Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers","Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers in Middle-Aged and Older Adults: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 30-75 years;\n* Total score \\> 5 points on the Pittsburgh Sleep Quality Index (PSQI) for sleep quality assessment;\n* Able to use personal mobile devices for WeChat, internet access, and related operations;\n* Informed about the intervention trial and willing to undergo sleep monitoring and other examinations during the study;\n* Commitment to consume coffee, strong tea, or alcohol ≤1 time per week during the trial period;\n\nExclusion Criteria:\n\n* Participation in any clinical trials or dietary\u002Fexercise intervention programs within the past 3 months or concurrently;\n* Diagnosis of major mental disorders or family history thereof, or current use of psychotropic drugs or mood-regulating medications;\n* Experiencing major psychological trauma (e.g., death of a close relative, significant financial loss) personally or within the family in the past 3 months;\n* Severe diseases affecting inflammatory levels and\u002For endocrine components (e.g., severe obesity, uncontrolled diabetes or poorly controlled blood glucose, myocardial infarction, cerebral infarction);\n* Current use of hormonal medications, beta-blockers, steroids, non-steroidal anti-inflammatory drugs (NSAIDs), etc.;\n* Use of medications potentially affecting sleep or aging biomarkers (e.g., melatonin, antidepressants, anxiolytics) within the past 3 months;\n* Plans for relocation or long-term travel within the next 6 months, which may hinder continuous intervention and follow-up.","30 Years",{"count":613,"type":21},80,[57],"The goal of this clinical trial is to evaluate the effects of Urolithin A (UA) and Fisetin on improving sleep and aging biomarkers in middle-aged and older adults. The main questions it aims to answer are:\n\nCan UA and Fisetin improve sleep quality in middle-aged and older adults? Do these substances have a positive effect on aging biomarkers, such as inflammation, oxidative stress, and aging-related proteins? Researchers will compare four groups: Placebo group (a look-alike substance that contains no drug), 500 mg UA group, 500 mg Fisetin group and 300 mg UA + 200 mg Fisetin group.\n\nParticipants will:\n\nTake the assigned capsules daily after breakfast for 12 weeks. Attend three clinic visits (baseline \\[Week 0\\], mid-intervention \\[Week 4\\], and post-intervention \\[Week 12\\]) including blood tests, sleep quality assessments (PSQI scale, actigraphy, polysomnography), and analysis of aging biomarkers (DNA methylation, inflammatory cytokines, etc.). Keep a sleep diary, complete a dietary survey, assess mental health, and measure frailty indicators. Provide stool and urine samples at baseline and post-intervention for gut microbiome and metabolite analysis. This trial aims to provide scientific evidence for the development of new nutritional intervention strategies to improve the healthy aging.",[617,618],"Sleep Disorder","Aging",[620,621,617,618],"Urolithin A","Fisetin","2026-01-16",{"date":624,"type":35},"2026-01-21",{"date":626,"type":35},"2025-09-16",{"date":183,"type":21},{"name":41,"class":42},""]